The Latest Cardiac and Vascular News
– Single doses resulted in potent, dose-dependent PCSK9 reductions of up to >90%, demonstrating best-in-class potential for the treatment of patients with high cholesterol at risk of cardiovascular disease CARLSBAD, Calif., Nov. 13, 2020 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that new data for ION449, an investigational antisense medicine designed to reduce […]
Pooled data analyses from Phase III ORION-9, -10 and -11 showed that inclisiran consistently reduced low-density lipoprotein cholesterol (LDL-C) by approximately 51% in both male and female adult patients and in three age categories1,2 Sustained LDL-C reduction with inclisiran was observed regardless of age or gender differences with two doses […]
VASCEPA®, compared with placebo, significantly reduced primary composite first and total major adverse cardiovascular events (MACE) in post hoc exploratory analyses of patients with a history of CABG by 24% and 36%, respectively, and key secondary composite first hard MACE, comprised of heart attacks, stroke and cardiovascular death, by 31% Administration of VASCEPA resulted in […]
Trial Met Primary Composite Endpoint of Reduction in Heart Failure Events or Cardiovascular Death; Did Not Meet Secondary Endpoints Including Reduction in Cardiovascular Death Effect of Omecamtiv Mecarbil Consistent Across Most Prespecified Subgroups with Potentially Greater Treatment Effect in Patients with Lower Ejection Fraction at Higher Risk Cytokinetics to Host Investor/Media […]
ECHO Data from EXPLORER-HCM Show Mavacamten Treatment Improved Cardiac Structure and Mitral Valve Function in Obstructive Hypertrophic Cardiomyopathy Patients Markers of Physical Activity from MAVERICK-HCM Accelerometry Data Correlated with Markers of HCM Severity in Non-Obstructive HCM Non-Clinical Data Show Mavacamten Surrogate Preserved Cardiac Function in Disease Model, Slowing Progression BRISBANE, Calif., Nov. 13, 2020 (GLOBE NEWSWIRE) — MyoKardia, Inc. (Nasdaq: MYOK) today presented clinical […]
Pooled data analyses from Phase III ORION-9, -10 and -11 showed that inclisiran consistently reduced low-density lipoprotein cholesterol (LDL-C) by approximately 51% in both male and female adult patients and in three age categories1,2 Sustained LDL-C reduction with inclisiran was observed regardless of age or gender differences1,2 with two doses a year, after an initial […]
– ARO-APOC3 achieved triglyceride reductions of 74-92% – ARO-ANG3 achieved triglyceride reductions of 29-75% and LCL-C reductions of 29-35% – Company to host upcoming KOL webinars on ARO-APOC3 and ARO-ANG3 PASADENA, Calif.–(BUSINESS WIRE)–Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced positive clinical data from multiple product candidates in its cardiometabolic pipeline at the American […]
TRANSLATE-HF study establishes the potential for broad use of the only SGLT2 inhibitor indicated in patients with heart failure with reduced ejection fraction with and without diabetes WILMINGTON, Del.–(BUSINESS WIRE)–New data from a large, contemporary US hospitalized heart failure (HF) registry confirms that four out of five (81.1%) patients with […]
The new program will launch for members from Vida’s national payer customers in December of this year with a full rollout in January of 2021 SAN FRANCISCO–(BUSINESS WIRE)–Expanding on its commitment to improve health outcomes for millions of lives, Vida Health announced a new app-based, coach-centered virtual congestive heart failure (CHF) management […]
Publication Explores the Beneficial Effects of Apabetalone on the Immune Cells of Diabetic Patients Event Reminder: Multiple Presentations on Apabetalone to be made during the American Heart Association Scientific Sessions – November 13-17 CALGARY, Alberta, Nov. 12, 2020 (GLOBE NEWSWIRE) — Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX:RVX) announced today the recent publication of an article titled: “BET protein inhibitor […]
